Matthew P. Morrow
23Patents
4h-index
13Co-inventors
56Inventor score
Filing activity: Apr 6, 2009 → Aug 12, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9272024B2 | Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same | Chemistry; Metallurgy | 9 | Active |
| US9750795B2 | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections | Chemistry; Metallurgy | 7 | Active |
| US8298820B2 | Influenza nucleic acid molecules and vaccines made therefrom | Chemistry; Metallurgy | 7 | Active |
| US9981036B2 | Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same | Chemistry; Metallurgy | 6 | Active |
| US10071154B2 | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same | Emerging Cross-Sectional Technologies | 2 | Active |
| US9192660B2 | Influenza nucleic acid molecules and vaccines made therefrom | Chemistry; Metallurgy | 1 | Active |
| US10363302B2 | Influenza nucleic acid molecules and vaccines therefrom | Chemistry; Metallurgy | 0 | Active |
| US11241496B2 | Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same | Chemistry; Metallurgy | 0 | Active |
| US12280108B2 | Vaccines having an antigen and interleukin-21 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10166288B2 | Vaccines having an antigen and interleukin-21 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10925961B2 | Vaccines with CD40 ligand as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10980870B2 | Proteins comprising MRSA Pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections | Chemistry; Metallurgy | 0 | Active |
| US11007265B2 | Vaccines having an antigen and interleukin-21 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10022434B2 | Influenza nucleic acid molecules and vaccines made therefrom | Chemistry; Metallurgy | 0 | Active |
| US10064931B2 | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections | Chemistry; Metallurgy | 0 | Active |
| US11998598B2 | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same | Emerging Cross-Sectional Technologies | 0 | Active |
| US9884106B2 | Influenza nucleic acid molecules and vaccines made therefrom | Chemistry; Metallurgy | 0 | Active |
| US12350318B2 | Combination therapy to treat brain cancer | Chemistry; Metallurgy | 0 | Active |
| US11027009B2 | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same | Emerging Cross-Sectional Technologies | 0 | Active |
| US9669091B2 | Vaccines having an antigen and interleukin-23 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10646563B2 | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using | Emerging Cross-Sectional Technologies | 0 | Active |
| US10933130B2 | Vaccines with interleukin-33 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
| US10130705B2 | Vaccines with interleukin-33 as an adjuvant | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.